A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses

Annals of the Rheumatic Diseases

Volumn 73, Issue 2, 2014, Pages 446-454

  Wei, Jun ^a   Zhu, Hongyan ^a   Komura, Kazuhiro ^a   Lord, Gabriel ^a   Tomcik, Michal ^b   Wang, Wenxia ^a   Doniparthi, Sruthi ^a   Tamaki, Zenshiro ^a   Hinchcliff, Monique ^a   Distler, Joerg H W ^c   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BARDOXOLONE; BLEOMYCIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN KINASE B; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRITERPENOID;

ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; EXPERIMENTAL FIBROSIS; FEMALE; FIBROGENESIS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MONOLAYER CULTURE; MOUSE; NONHUMAN; ORGAN CULTURE; PRIORITY JOURNAL; SCLERODERMA; SKIN FIBROBLAST; SKIN FIBROSIS;

EID: 84891678660     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202716     Document Type: Article

References (56)

1. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2012;8:42-54.
2. Rosenbloom J, Castro SV, Jimenez SA. Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies. Ann Intern Med 2010;152:159-66.
3. Varga J, Pasche B. Transforming growth factor beta as a therapeutic target in systemic sclerosis. Nat Rev Rheumatol 2009;5:200-6.
4. Sargent JL, Milano A, Bhattacharyya S, et al. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010;130:694-705.
5. Milano A, Pendergrass SA, Sargent JL, et al. Molecular subsets in the gene expression signatures of scleroderma skin. PLoS One 2008;3:e2696.
6. Wei J, Bhattacharyya S, Varga J. Peroxisome proliferator-activated receptor gamma: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol 2010;22:671-6.
7. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005;123:993-9.
8. Tontonoz P, Spiegelman BM. Fat and beyond: the diverse biology of PPARgamma. Annu Rev Biochem 2008;77:289-312.
9. Wei J, Bhattacharyya S, Jain M, et al. Regulation of matrix remodeling by peroxisome proliferator-activated receptor-gamma: a novel link between metabolism and fibrogenesis. Open Rheum J 2012;6:103-15.
10. Ghosh AK, Bhattacharyya S, Lakos G, et al. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004;50:1305-18. (Pubitemid 38480842)
11. Wu M, Melichian DS, Chang E, et al. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 2009;174:519-33.
12. Zheng F, Fornoni A, Elliot SJ, et al. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 2002;282:F639-48. (Pubitemid 34654511)
13. Burgess HA, Daugherty LE, Thatcher TH, et al. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005;288:L1146-53. (Pubitemid 40695441)
14. Shi-wen X, Eastwood M, Stratton RJ, et al. Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts. Rheumatology (Oxford) 2010;49:259-63.
15. Galli A, Crabb DW, Ceni E, et al. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology 2002;122:1924-40. (Pubitemid 34651436)
16. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;106:3126-32. (Pubitemid 35440299)
17. Kawai T, Masaki T, Doi S, et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009;89:47-58.
18. Kapoor M, McCann M, Liu S, et al. Loss of peroxisome proliferator- activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009;60:2822-9.
19. Miyahara T, Schrum L, Rippe R, et al. Peroxisome proliferator-activated receptors and hepatic stellate cell activation. J Biol Chem 2000;275:35715-22.
20. Yang L, Chan CC, Kwon OS, et al. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2006;291:G902-11. (Pubitemid 44772017)
21. Karnik P, Tekeste Z, McCormick TS, et al. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol 2009;129:1243-57.
22. Wei J, Ghosh AK, Sargent JL, et al. PPARgamma downregulation by TGFbeta in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010;5:e13778.
23. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71. (Pubitemid 46919772)
24. Higgins LS, Depaoli AM. Selective peroxisome proliferator-activated receptor gamma (PPARgamma) modulation as a strategy for safer therapeutic PPARgamma activation. Am J Clin Nutr 2010;91:267S-72S.
25. Honda T, Rounds BV, Gribble GW, et al. Design and synthesis of 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages. Bioorg Med Chem Lett 1998;8:2711-14. (Pubitemid 28496657)
26. Wang Y, Porter WW, Suh N, et al. A synthetic triterpenoid, 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol 2000;14:1550-6.
27. Liby K, Hock T, Yore MM, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res 2005;65:4789-98. (Pubitemid 40740817)
28. Petronelli A, Pannitteri G, Testa U. Triterpenoids as new promising anticancer drugs. Anticancer Drugs 2009;20:880-92.
29. Sogno I, Vannini N, Lorusso G, et al. Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids. Recent Results Cancer Res 2009;181:209-12.
30. Ferguson HE, Kulkarni A, Lehmann GM, et al. Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol 2009;41:722-30.
31. Kuriyan AE, Lehmann GM, Kulkarni AA, et al. Electrophilic PPARgamma ligands inhibit corneal fibroblast to myofibroblast differentiation in vitro: A potentially novel therapy for corneal scarring. Exp Eye Res 2012;94:136-45.
32. Mori Y, Ishida W, Bhattacharyya S, et al. Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum 2004;50:4008-21. (Pubitemid 39643950)
33. Wei J, Ghosh AK, Sargent JL, et al. PPARgamma downregulation by TGFss in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010;5:e13778.
34. Meyers C, Laimins LA. In vitro systems for the study and propagation of human papillomaviruses. Curr Top Microbiol Immunol 1994;186:199-215. (Pubitemid 24099092)
35. Getsios S, Simpson CL, Kojima S, et al. Desmoglein 1-dependent suppression of EGFR signaling promotes epidermal differentiation and morphogenesis. J Cell Biol 2009;185:1243-58.
36. Akhmetshina A, Palumbo K, Dees C, et al. Activation of canonical Wnt signalling is required for TGF-beta-mediated fibrosis. Nat Commun 2012;3:735.
37. Arimura N, Horiba T, Imagawa M, et al. The peroxisome proliferator-activated receptor gamma regulates expression of the perilipin gene in adipocytes. J Biol Chem 2004;279:10070-6. (Pubitemid 38372610)
38. Zahouani H, Pailler-Mattei C, Sohm B, et al. Characterization of the mechanical properties of a dermal equivalent compared with human skin in vivo by indentation and static friction tests. Skin Res Technol 2009;15:68-76.
39. Auxenfans C, Fradette J, Lequeux C, et al. Evolution of three dimensional skin equivalent models reconstructed in vitro by tissue engineering. Eur J Dermatol 2009;19:107-13.
40. Bradshaw AD, Puolakkainen P, Dasgupta J, et al. SPARC-null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter and reduced tensile strength. J Invest Dermatol 2003;120:949-55. (Pubitemid 36702902)
41. Kulkarni AA, Thatcher TH, Olsen KC, et al. PPAR-gamma ligands repress TGFbeta-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PLoS One 2011;6:e15909.
42. Mori Y, Chen SJ, Varga J. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 2003;48:1964-78. (Pubitemid 36828692)
43. Huang JT, Welch JS, Ricote M, et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999;400:378-82. (Pubitemid 29344205)
44. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67. (Pubitemid 46348510)
45. Ghosh AK, Bhattacharyya S, Wei J, et al. Peroxisome proliferator- activated receptor-{gamma} abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. Faseb J 2009;23:2968-77.
46. Batteux F, Kavian N, Servettaz A. New insights on chemically induced animal models of systemic sclerosis. Curr Opin Rheumatol 2011;23:511-18.
47. Suh N, Roberts AB, Reffey S Birkey, et al. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res 2003;63:1371-6. (Pubitemid 36348719)
48. Liao D, Liu Z, Wrasidlo WJ, et al. Targeted therapeutic remodeling of the tumor microenvironment improves an HER-2 DNA vaccine and prevents recurrence in a murine breast cancer model. Cancer Res 2011;71:5688-96.
49. Artaud-Macari E, Goven D, Brayer S, et al. Nrf2 nuclear translocation induces myofibroblastic dedifferentiation in idiopathic pulmonary fibrosis. Antioxid Redox Signal 2013;18:66-79.
50. Yates MS, Kwak MK, Egner PA, et al. Potent protection against aflatoxin-induced tumorigenesis through induction of Nrf2-regulated pathways by the triterpenoid 1-[2-cyano-3-, 12-dioxooleana-1, 9 (11)-dien-28-oyl]imidazole. Cancer Res 2006;66:2488-94.
51. Ling X, Konopleva M, Zeng Z, et al. The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res 2007;67:4210-18. (Pubitemid 46815067)
52. Vannini N, Lorusso G, Cammarota R, et al. The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. Mol Cancer Ther 2007;6(12 Pt 1):3139-46.
53. Deeb D, Gao X, Liu Y, et al. Synthetic triterpenoid CDDO prevents the progression and metastasis of prostate cancer in TRAMP mice by inhibiting survival signaling. Carcinogenesis 2011;32:757-64.
54. Liby KT, Sporn MB. Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev 2012;64:972-1003.
55. Thomas MC, Cooper ME. Diabetes: bardoxolone improves kidney function in type 2 diabetes. Nat Rev Nephrol 2011;7:552-3.
56. Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 2011;365:327-36.